Carmen Bozic, Vertex CMO

FDA ex­pands ap­proval for Ver­tex's CF drug Orkam­bi to in­fants un­der two years of age

The FDA on Fri­day ex­pand­ed its ap­proval of Ver­tex’s block­buster cys­tic fi­bro­sis pill Orkam­bi to in­clude chil­dren be­tween 12 and 24 months.

Orkam­bi first won …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.